Summary
ABSTRACT Mycobacterium tuberculosis (Mtb) infection is a global health pandemic claiming 1.5 million lives each year. Current tuberculosis (TB) therapies are challenged by drug resistance, characterized by mutations that render approved drugs increasingly less effective. PZA is a critical component of first-line TB therapy. It allows for shorter treatment regimens and is unrivaled in its efficacy against non-replicating, persister Mtb populations, which decrease the chance of resistance and relapse respectively. If the past predicts the future, the success of many short course and ultra-short
